Monday 15 June 2020
Here is our summary of the day's hottest RNS alerts from across London's Alternative Investments Market (AIM).
Yourgene Health (YGEN.LSE)
CE-IVD mark received for Illumina-based IONA® test
Yourgene, a leading international molecular diagnostics group, announced that it has received CE-IVD marking for its Illumina-based IONA® test, the Company's flagship non-invasive prenatal test ("NIPT") product for Down's syndrome and other genetic disorders.
The newly approved test, the ION A® Nx NIPT Workflow ("IONA ® Nx"), will now be readied for commercial launch across the European Union, including the UK, as well as other countries that accept the CE-IVD mark.
The IONA® Nx, is an in vitro nucleic acid screening test that measures the likelihood that a pregnant woman is carrying a fetus with Trisomy 13, 18 or 21. It is a laboratory based test that has been developed to run on the Illumina's NextSeq 550Dx instrument, a next generation sequencing ("NGS") platform.
As Europe emerges from the restrictions implemented due to the coronavirus pandemic, the Company expects to roll-out the ION A® Nx to its laboratory customers across the UK and Europe in the coming months, as well as establishing its own laboratory based test service using ION A® Nx at the Company's facilities in Manchester.
Yourgene will work with its customers to allow technical installations to take place that ensure social distancing within the lab and remote work will be undertaken to ensure customers have access to the IONA Nx as soon as possible, despite current travel restrictions.
Key features of the new IONA Nx NIPT workflow include:
IONA® Nx utilises advanced proprietary sample preparation technologies
The test process has been simplified therefore reducing the need for instrumentation capital expenditure
IONA® Nx has been designed to offer flexibility and scalability to suit varying customer needs
Further details about IONA® Nx will be announced following the full commercial launch and a further update will be provided to shareholders in due course.
Open Orphan Plc (ORPH.LSE)
Positive Phase I results published in The Lancet
Positive results from the Phase I study of the AGS-v vaccine developed by an Open Orphan joint venture, Imutex Limited, have been published in the peer reviewed journal The Lancet.
AGS-v is a first-in-class mosquito saliva, standalone, vaccine candidate designed to protect against mosquito-borne diseases carried in the saliva such as Zika, Malaria, Dengue Fever and West Nile Virus.
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study modelsis pleased to announce that the results of a randomised, placebo-controlled, double-blind, phase 1 trial of AGS-v have been published in The Lancet. AGS-v has been developed by Imutex Limited, in which Open Orphan owns a 49% stake in conjunction with the SEEK Group.
The first trial of AGS-v, a first-in-class "mosquito saliva vaccine" in humans
The trial indicated that the vaccine is safe and induces a strong immune response in healthy volunteers
These positive findings suggest that AGS-v is now ready to advance to Phase II
Numerous studies have shown that protection from diseases carried in saliva is possible if you alter the immune response to saliva. Using natural saliva to achieve this not viable. AGS-v is designed as a transformational vaccine, the first ever mosquito synthetic saliva vaccine designed in to protect against mosquito-borne diseases carried in the saliva such as Zika, Malaria, Dengue Fever, West Nile Virus etc. AGS-v is designed to provoke an immune response against mosquito saliva, rather than any specific parasites, viruses, or bacteria the mosquito might transmit making it an important tool in the fight against mosquito-borne diseases.
In the new study published in The Lancet, NIAID scientists describe the results of the Phase 1 trial of the vaccine as "encouraging and worthy of further study".
The Trial Results
The double-blind study, which began in 2017 at the NIH Clinical Center in Bethesda, Maryland, was the first trial of this so-called "mosquito saliva vaccine" in humans.
The volunteers' blood tests showed that the vaccine in combination with the adjuvant produced a significant immune response to mosquito salivary peptides. Further, this immune response was not accompanied by a worse reaction to mosquito bites.
The study's results are promising and suggest that further research to test the vaccine's efficacy against individual pathogens, followed by larger field studies, would be worthwhile. A widely available "universal" vaccine could provide protection against emerging and re-emerging mosquito-borne diseases as they arise, allowing public health officials to quickly respond to new outbreaks and epidemics without waiting for new treatments or vaccines to be developed.
Bango Plc (BGO.LSE)
Bango launches SoftBank payment option for Amazon.co.jp
SoftBank customers can use carrier billing to purchase retail goods on Amazon.co.jp.
Bango now powers carrier billing for Amazon customers in Japan across big three mobile operators.
Bango, the mobile commerce company, announces that it has enabled carrier billing for mobile operator SoftBank Corp., on Amazon.co.jp. Amazon customers with a SoftBank mobile phone account can now pay for goods, membership fees and subscription services, and charge the cost to their mobile phone bill.
To use this payment option, a SoftBank subscriber simply adds carrier billing as a payment option in their Amazon.co.jp account and then purchases can be made from any device, with the cost charged to their phone bill.
Bango now powers carrier billing for Amazon.co.jp across Japan's three largest operators, adding SoftBank in addition to NTT Docomo and KDDI. With 177M subscriptions (source: Statista 2020) across a population of 130M (source: World Bank), Japan is one of the most highly penetrated mobile markets in the world.
Carrier billing enables customers to make purchases instantly, without the need to enter their card details online. It is a highly effective way to acquire, monetize and engage customers. Bango technology ensures payment reliability, security and customer success.